IRMD IRADIMED CORP revenue, earnings and financials
For the quarter ended June 30, 2026, IRADIMED CORP reported revenue of $20.5M (up 0.3% from a year earlier), net income of $5.22M and diluted EPS of $0.41; over the last four quarters revenue was $86.3M and net income $23.1M; for the fiscal year ended December 2025 revenue was $83.8M, up 14.4% on the year before.
IRMD annual revenue and earnings
- Fiscal year ended Dec 2025: revenue $83.8M, gross profit $64.3M, operating income $26.1M, net income $22.5M (margin 26.8%), EPS $1.75
- Fiscal year ended Dec 2024: revenue $73.2M, gross profit $56.4M, operating income $22.0M, net income $19.2M (margin 26.3%), EPS $1.50
- Fiscal year ended Dec 2023: revenue $65.6M, gross profit $50.2M, operating income $20.0M, net income $17.2M (margin 26.2%), EPS $1.35
- Fiscal year ended Dec 2022: revenue $53.3M, gross profit $41.3M, operating income $15.6M, net income $12.8M (margin 24.1%), EPS $1.02
- Fiscal year ended Dec 2021: revenue $41.8M, gross profit $32.0M, operating income $9.82M, net income $9.33M (margin 22.3%), EPS $0.74
IRMD quarterly revenue and earnings
- Quarter ended Jun 30, 2026: revenue $20.5M (up 0.3% year over year), net income $5.22M, EPS $0.41
- Quarter ended Mar 31, 2026: revenue $22.0M (up 12.6% year over year), net income $5.82M, EPS $0.45
- Quarter ended Dec 31, 2025 (from the annual report): revenue $22.7M (up 17.0% year over year), net income $6.44M, EPS $0.50
- Quarter ended Sep 30, 2025: revenue $21.2M (up 15.7% year over year), net income $5.58M, EPS $0.43
- Quarter ended Jun 30, 2025: revenue $20.4M (up 13.8% year over year), net income $5.77M, EPS $0.45
- Quarter ended Mar 31, 2025: revenue $19.5M (up 10.9% year over year), net income $4.69M, EPS $0.37
- Quarter ended Dec 31, 2024 (from the annual report): revenue $19.4M (up 11.1% year over year), net income $5.15M, EPS $0.40
- Quarter ended Sep 30, 2024: revenue $18.3M (up 11.0% year over year), net income $5.05M, EPS $0.40
- Quarter ended Jun 30, 2024: revenue $17.9M (up 11.1% year over year), net income $4.90M, EPS $0.38
- Quarter ended Mar 31, 2024: revenue $17.6M (up 13.7% year over year), net income $4.14M, EPS $0.32
- Quarter ended Dec 31, 2023 (from the annual report): revenue $17.5M (up 17.4% year over year), net income $4.54M, EPS $0.35
- Quarter ended Sep 30, 2023: revenue $16.5M (up 23.1% year over year), net income $5.07M, EPS $0.40
- Quarter ended Jun 30, 2023: revenue $16.1M (up 26.8% year over year), net income $4.18M, EPS $0.33
- Quarter ended Mar 31, 2023: revenue $15.5M (up 25.7% year over year), net income $3.41M, EPS $0.27
- Quarter ended Dec 31, 2022 (from the annual report): revenue $14.9M (up 25.2% year over year), net income $3.67M, EPS $0.29
- Quarter ended Sep 30, 2022: revenue $13.4M (up 22.9% year over year), net income $3.43M, EPS $0.27
- Quarter ended Jun 30, 2022: revenue $12.7M (up 29.7% year over year), net income $3.24M, EPS $0.26
- Quarter ended Mar 31, 2022: revenue $12.3M (up 33.5% year over year), net income $2.49M, EPS $0.20
- Quarter ended Dec 31, 2021 (from the annual report): revenue $11.9M, net income $3.89M, EPS $0.31
- Quarter ended Sep 30, 2021: revenue $10.9M, net income $2.58M, EPS $0.20
IRMD cash flow, buybacks and dividends
- Fiscal year ended Dec 2025: operating cash flow $24.9M, share buybacks n/a
- Fiscal year ended Dec 2024: operating cash flow $25.6M, share buybacks n/a
- Fiscal year ended Dec 2023: operating cash flow $13.5M, share buybacks n/a
- Fiscal year ended Dec 2022: operating cash flow $10.0M, share buybacks n/a
- Fiscal year ended Dec 2021: operating cash flow $11.3M, share buybacks n/a
IRMD balance sheet
- Jun 30, 2026: cash $59.1M, total assets $115M, total liabilities $13.2M, shareholders' equity $102M
- Mar 31, 2026: cash $56.4M, total assets $114M, total liabilities $15.9M, shareholders' equity $98.5M
- Dec 31, 2025: cash $51.2M, total assets $109M, total liabilities $14.2M, shareholders' equity $94.6M
- Sep 30, 2025: cash $56.5M, total assets $115M, total liabilities $16.4M, shareholders' equity $98.4M
- Jun 30, 2025: cash $53.0M, total assets $106M, total liabilities $12.1M, shareholders' equity $94.3M
- Mar 31, 2025: cash $50.3M, total assets $102M, total liabilities $11.7M, shareholders' equity $90.1M
- Dec 31, 2024: cash $52.2M, total assets $98.3M, total liabilities $11.5M, shareholders' equity $86.8M
- Sep 30, 2024: cash $51.7M, total assets $94.2M, total liabilities $10.8M, shareholders' equity $83.4M
What is IRMD's revenue?
IRADIMED CORP reported $86.3M of revenue over its last four quarters, through June 30, 2026.
Is IRMD profitable?
Yes. IRADIMED CORP earned $23.1M over the last four quarters.
What is IRMD's EPS?
Diluted earnings per share over the last four quarters were $1.79; $0.41 in the latest quarter.